Cargando…
Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
AIMS/INTRODUCTION: There is little information regarding how to use insulin degludec (D) when diabetic patients are preparing for total colonoscopy (TCS). MATERIALS AND METHODS: A total of 12 patients with type 2 diabetes treated with insulin D and scheduled to undergo TCS were enrolled in the prese...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847892/ https://www.ncbi.nlm.nih.gov/pubmed/27330724 http://dx.doi.org/10.1111/jdi.12409 |
_version_ | 1782429276982738944 |
---|---|
author | Takeishi, Soichi Mori, Akihiro Fushimi, Nobutoshi Hachiya, Hiroki Yumura, Takayuki Ito, Shun Shibuya, Takashi Ohashi, Noritsugu Kawai, Hiromi |
author_facet | Takeishi, Soichi Mori, Akihiro Fushimi, Nobutoshi Hachiya, Hiroki Yumura, Takayuki Ito, Shun Shibuya, Takashi Ohashi, Noritsugu Kawai, Hiromi |
author_sort | Takeishi, Soichi |
collection | PubMed |
description | AIMS/INTRODUCTION: There is little information regarding how to use insulin degludec (D) when diabetic patients are preparing for total colonoscopy (TCS). MATERIALS AND METHODS: A total of 12 patients with type 2 diabetes treated with insulin D and scheduled to undergo TCS were enrolled in the present study. A continuous glucose monitoring device was attached to each patient for 4 days, from two evenings before TCS to the morning after the procedure. The patients fasted for 24 h, starting after 18.00 h the day before TCS. Insulin D was only discontinued the morning of the day TCS was carried out. RESULTS: No patients experienced hypoglycemia during the daytime fasting period (08.00–18.00 h the day of TCS); the hypoglycemic index, mean glucose level, and standard deviation were 0, 141.3 ± 31.5 mg/dL and 15.6 ± 6.5 mg/dL. The mean glucose level and standard deviation during the daytime fasting period were significantly lower than during the daytime control period (08.00–18.00 h the day before TCS; P = 0.003, P = 0.001, respectively). The mean fasting glucose and fasting plasma glucose levels were significantly correlated (r = 0.78, P = 0.002), as were both the mean glucose level and standard deviation during the daytime control period, and the change in the mean glucose level (fasting period minus control period; r = −0.79, P = 0.002, and r = −0.69, P = 0.01, respectively). CONCLUSIONS: Patients can safely undergo TCS when insulin D is discontinued only once on the day of the procedure. |
format | Online Article Text |
id | pubmed-4847892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48478922016-06-21 Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring Takeishi, Soichi Mori, Akihiro Fushimi, Nobutoshi Hachiya, Hiroki Yumura, Takayuki Ito, Shun Shibuya, Takashi Ohashi, Noritsugu Kawai, Hiromi J Diabetes Investig Articles AIMS/INTRODUCTION: There is little information regarding how to use insulin degludec (D) when diabetic patients are preparing for total colonoscopy (TCS). MATERIALS AND METHODS: A total of 12 patients with type 2 diabetes treated with insulin D and scheduled to undergo TCS were enrolled in the present study. A continuous glucose monitoring device was attached to each patient for 4 days, from two evenings before TCS to the morning after the procedure. The patients fasted for 24 h, starting after 18.00 h the day before TCS. Insulin D was only discontinued the morning of the day TCS was carried out. RESULTS: No patients experienced hypoglycemia during the daytime fasting period (08.00–18.00 h the day of TCS); the hypoglycemic index, mean glucose level, and standard deviation were 0, 141.3 ± 31.5 mg/dL and 15.6 ± 6.5 mg/dL. The mean glucose level and standard deviation during the daytime fasting period were significantly lower than during the daytime control period (08.00–18.00 h the day before TCS; P = 0.003, P = 0.001, respectively). The mean fasting glucose and fasting plasma glucose levels were significantly correlated (r = 0.78, P = 0.002), as were both the mean glucose level and standard deviation during the daytime control period, and the change in the mean glucose level (fasting period minus control period; r = −0.79, P = 0.002, and r = −0.69, P = 0.01, respectively). CONCLUSIONS: Patients can safely undergo TCS when insulin D is discontinued only once on the day of the procedure. John Wiley and Sons Inc. 2015-09-06 2016-05 /pmc/articles/PMC4847892/ /pubmed/27330724 http://dx.doi.org/10.1111/jdi.12409 Text en © 2015 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Articles Takeishi, Soichi Mori, Akihiro Fushimi, Nobutoshi Hachiya, Hiroki Yumura, Takayuki Ito, Shun Shibuya, Takashi Ohashi, Noritsugu Kawai, Hiromi Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring |
title | Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring |
title_full | Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring |
title_fullStr | Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring |
title_full_unstemmed | Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring |
title_short | Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring |
title_sort | evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847892/ https://www.ncbi.nlm.nih.gov/pubmed/27330724 http://dx.doi.org/10.1111/jdi.12409 |
work_keys_str_mv | AT takeishisoichi evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring AT moriakihiro evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring AT fushiminobutoshi evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring AT hachiyahiroki evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring AT yumuratakayuki evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring AT itoshun evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring AT shibuyatakashi evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring AT ohashinoritsugu evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring AT kawaihiromi evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring |